BPC-157: the state of the preclinical evidence
A pentadecapeptide derived from a gastric juice protein, with a large rodent literature and a thin clinical one. A neutral map of where the evidence stands, what models dominate it, and where the gaps are.
BPC-157 (sequence GQEPRPGKPWGWPRPGQ) is among the most-studied peptides in the rodent literature and among the least-studied in humans. That asymmetry is the single most important fact about its evidence base, and it shapes how any research program should treat published claims.
Where the literature is dense
Rodent models dominate: tendon and ligament injury, gastric ulcer healing, and endothelial protection appear repeatedly across independent groups. The recurring mechanistic theme is angiogenesis and nitric-oxide-mediated endothelial protection, though the precise receptor-level story remains contested.
Where it is thin
Human data are limited to small, mostly non-randomized studies and case series. No large randomized controlled trial establishes effect sizes in humans for any indication, and pharmacokinetic data in humans are sparse. Claims that leap from rodent wound models to human outcomes are extrapolations, and should be labeled as such.
Stability and handling notes in the literature
Published work describes unusual stability for a peptide of this class, including resistance to certain proteases, which is part of why it survives as a research reagent. Storage and reconstitution practice still follows ordinary lyophilized-peptide discipline: cold, dry, and protected from repeated freeze-thaw.